These include axitinib (tyrosine kinase inhibitor selective to VEGF-R1, -R2, -R3) for renal cell carcinoma [4]; bevacizumab (anti-VEGF humanized Ab) for several types of cancer, including lung, colorectal and cervical cancers [5]; sunitinib (triple-blocker, Abs to VEGF-R2, PDGF-Rb, and c-kit) for gastrointestinal stromal tumor, pancreatic, and renal cancers [6]; and several others [1,3]. This evidence concerns the gene KDR and renal carcinoma.